Palvella Therapeutics, Inc reports a Return on Equity (ROE) of -21.22%.

What is PVLA's dividend yield?

Palvella Therapeutics, Inc offers a dividend yield of 0.00%.

What is PVLA's Quality Score?

Our AI rates PVLA's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy PVLA?

Our AI Timing Score for PVLA is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does PVLA belong to?

Palvella Therapeutics, Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Palvella Therapeutics, Inc (PVLA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

PVLA AI Analysis Summary

Our AI summary for PVLA: Palvella Therapeutics, Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -21.22%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

PVLA

Palvella Therapeutics, Inc

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 140.78

11.21 (7.96%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-21.2%

ROE

-18.7%

ROA

0.00%

Div Yield

PALVELLA THERAPEUTICS, INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 140.78 Price 11.21 (7.96%) Day Change	NEWS SCORE: N/A

PVLA, the overall quality is not good ( Quality = 15) but the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	140.78
PBV / Sector	8.58 / 44,219.29
Earning Per Share	-3.48

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	31.05 M GREAT
Average 1W Daily Value	25.59 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.22
NPM Average (%) / Sector	-128.47 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-18.69 / 185,260.96
ROA Average (%) / Sector	-12.45 / 36,684.70
ROA Change Average (%) / Sector	-37.45 / 422,221.66
ROE (%) / Sector	-21.22 / 243,762.23
ROE Average (%) / Sector	-107.25 / 48,758.47
ROE Change Average (%) / Sector	-45.03 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:02:02
Symbol	PVLA
Name	PALVELLA THERAPEUTICS, INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	14.34 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,994.23 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 353 W. Lancaster Avenue, Wayne, PA, United States, 19087

Phone: 484 253 1461

Website: https://palvellatx.com

Sector: Healthcare >> Biotechnology

Description: Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.